The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2025

Filed:

Oct. 09, 2019
Applicants:

Synergene Therapeutics, Inc., Potomac, MD (US);

Georgetown University, Washington, DC (US);

Inventors:

Esther H. Chang, Potomac, MD (US);

Joe B. Harford, Potomac, MD (US);

Sang Soo Kim, Rockville, MD (US);

Assignees:

SYNERGENE THERAPEUTICS, INC., Potomac, MD (US);

GEORGETOWN UNIVERSITY, Washington, DC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2005.12); A61K 31/282 (2005.12); A61K 38/17 (2005.12); A61K 39/395 (2005.12); A61P 35/00 (2005.12); A61P 35/04 (2005.12); C07K 16/28 (2005.12);
U.S. Cl.
CPC ...
A61K 9/127 (2012.12); A61K 31/282 (2012.12); A61K 38/1709 (2012.12); A61K 38/1758 (2012.12); A61K 39/3955 (2012.12); A61P 35/00 (2017.12); A61P 35/04 (2017.12); C07K 16/2818 (2012.12); C07K 16/2827 (2012.12); C07K 16/2881 (2012.12); C07K 2317/21 (2012.12); C07K 2317/24 (2012.12); C07K 2317/56 (2012.12);
Abstract

This invention provides methods to overcome the current limitations of immune checkpoint immunotherapy to provide more effective methods of treating cancer. In embodiments this invention provides a means of using of p53 gene therapy to augment immune checkpoint inhibition by combining antibodies targeting immune checkpoint molecules with SGT-53, a nanomedicine carrying a plasmid encoding human wild-type p53. This invention provides means of increasing tumor immunogenicity, enhancing both innate and adaptive immune responses, and reducing tumor-induced immunosuppression, sensitizing otherwise refractory tumors to anti-immune checkpoint antibodies. In other embodiments this invention also unexpectedly reduces immune-related toxicities that are seen with immunotherapies.


Find Patent Forward Citations

Loading…